Abstract:ABSTRACT Aim: ICAN study (NCT01106781) was designed to investigate EGFR gene mutation status, clinical outcomes and recurrent risk factors in early stage Chinese NSCLC patients with adenocarcinoma (ADC) histology after complete resection. Methods: Patients were ≥18 years old, with histological diagnosis of NSCLC ADC, and received surgical complete resection. Tumor sample EGFR mutation status was determined according to clinical routine practice. All eligible patients were followed up for 3 years to collect the clinical information and the survival outcomes. Results: Of 568 patients from 26 sites, 313 (55.1%) patients were EGFR mutation positive. The most common mutations were exon19 deletion and exon 21 L858R mutation found in 139 (24.5%) and 128 (22.5%) patients respectively. 4(0.7%) patients were exon19 deletion + exon 21 L858R mutations and 42 (7.4%) patients were with rare mutations. Frequency of EGFR mutation was not correlated to postoperative pathological stage (P = 0.1047). The 3-year DFS was 58.8%. Subgroup analysis found that 65.6% 3y DFS in EGFR mutant patients and 56.8% in wild type patients (P = 0.0347); 63.8% in exon 19 deletion, 67.2% in exon21 L858R mutation, 100% in exon19 deletion + exon 21 L858R mutations and 63.4% in rare mutations (p = 0.5810). There were 50.7% of the patients who received adjuvant therapy, among which 45.4% received chemotherapy, 4.6% received radiotherapy and 1.8% received TKI therapy, respectively. Among EGFR mutant patients, adjuvant therapy correlated significantly to 3-year DFS (P = 0.0024), but was not significant when adjusted for postoperative pathological stage. Female showed a higher 3-year DFS rate than male patients (67.90% vs 55.70%, P = 0.0041). There was statistically significant difference of 3-year DFS among patients with different postoperative pathologic stage (P Conclusions: The overall EGFR mutation positive rate in operable Chinese ADC was 55.1%. 3-year DFS rate was 58.8%. EGFR mutant patients have a favorable 3-year DFS compared with EGFR wild type. Postoperative pathologic stage had a statistically significant association with 3-year DFS, while age, smoking pack-years didn't show statistically significant associations with 3-year DFS. Disclosure: Y. Wu: Recieved speaker fees from AstraZeneca, Roche, Eli Lilly, Sanofi, Pfizer. All other authors have declared no conflicts of interest.

Pan-Driver-Negatives Versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity

The prognostic impact of epidermal growth factor receptor mutation in clinical stage I lung adenocarcinoma

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

Impact of a Ground-glass Opacity Component on C-Stage IA Lung Adenocarcinoma

Prognostic Value of Epidermal Growth Factor Receptor Gene Mutation in Resected Lung Adenocarcinoma

High-resolution Computed Tomography Findings Independently Predict Epidermal Growth Factor Receptor Mutation Status in Ground-Glass Nodular Lung Adenocarcinoma.

A Prospective Comparison Study on EGFR Mutations by Direct Sequencing and ARMS in Completely Resected Chinese Non-Small Cell Lung Cancer with Adenocarcinoma Histology (ICAN).

Distinguishing EGFR mutant subtypes in stage IA non-small cell lung cancer using the presence status of ground glass opacity and final histologic classification: a systematic review and meta-analysis

Clinicopathologic Features and Prognostic Value of Epidermal Growth Factor Receptor Mutation in Patients with Pt1a and Pt1b Invasive Lung Adenocarcinoma after Surgical Resection

Prognostic implications of CT-defined ground glass opacity in clinical stage I-IIA grade 3 invasive non-mucinous pulmonary adenocarcinoma

Prognosis of EGFR-mutant Advanced Lung Adenocarcinoma Patients with Different Intrathoracic Metastatic Patterns

Distinct Prognostic Factors in Patients with Stage I Non–Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions

Computed Tomography and Clinical Features Associated with Epidermal Growth Factor Receptor Mutation Status in Stage I/Ii Lung Adenocarcinoma

Ground Glass Nodules with Scattered or Eccentric Island‐shaped Consolidations May Have Poor Outcomes

Comprehensive Analysis of Mutational Profile and Prognostic Significance of Complex Glandular Pattern in Lung Adenocarcinoma

Ground Glass Opacities: Imaging, Pathology, and Gene Mutations

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?

Prognostic impact of ground-glass opacity components in lung cancer with lymph node metastasis

Egfr Mutation and Survival Outcomes in Patients with Completely Resected Lung Adenocarcinoma – a Multiple Centers, Non-Interventional Study (ican Trial)

Predictors of Pathologic Tumor Invasion and Prognosis for Ground Glass Opacity Featured Lung Adenocarcinoma

Solid Component Ratio Influences Prognosis of GGO-featured IA Stage Invasive Lung Adenocarcinoma